Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
Zevra Therapeutics Inc ( NASDAQ:ZVRA ) successfully launched Myle, the first FDA-approved therapy for Niemann-Pick disease type C, with 90 prescription enrollment forms submitted by October 31st. The company received a rare pediatric disease priority review voucher (PRV) with the approval of Myle, which they plan to monetize for non-dilutive capital. Zevra Therapeutics Inc ( NASDAQ:ZVRA ) completed an end of phase two meeting with the FDA for KP1077, receiving clear direction for a phase three path forward. The company has a strategic plan for 2025 focusing on commercial excellence, pipeline and innovation, talent and culture, and corporate foundation. Zevra Therapeutics Inc ( NASDAQ:ZVRA ) completed a public offering, raising approximately $64.5 million, extending their cash runway into 2027. The launch of Aprova, a treatment for urea cycle disorders, is underperforming with only three prescription enrollment forms received in the third quarter. Zevra Therapeutics Inc (
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CGlobeNewswire
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesGlobeNewswire
ZVRA
Earnings
- 11/12/24 - Miss
ZVRA
Sec Filings
- 11/22/24 - Form 8-K
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- ZVRA's page on the SEC website